Bruker Corporation (NASDAQ:BRKR) Given Average Rating of “Hold” by Brokerages

Bruker Corporation (NASDAQ:BRKR) has been given an average rating of “Hold” by the fifteen brokerages that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $50.3846.

A number of research firms have recently issued reports on BRKR. Guggenheim upped their price target on Bruker from $53.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Jefferies Financial Group set a $50.00 target price on Bruker in a research note on Thursday, February 12th. Barclays lowered their price target on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Finally, Rothschild & Co Redburn set a $60.00 price objective on shares of Bruker in a report on Thursday, November 20th.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $49.20, for a total value of $98,400.00. Following the completion of the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $6,319,395.60. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

Several hedge funds have recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd lifted its stake in Bruker by 5.4% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after buying an additional 761,258 shares during the last quarter. State Street Corp raised its position in Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after purchasing an additional 91,706 shares during the last quarter. AQR Capital Management LLC boosted its stake in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the period. Sculptor Capital LP grew its position in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after purchasing an additional 476,363 shares during the last quarter. Finally, Brown Advisory Inc. grew its position in Bruker by 13.9% during the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after purchasing an additional 336,026 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Stock Up 0.3%

NASDAQ:BRKR opened at $39.89 on Thursday. The firm has a market capitalization of $6.06 billion, a P/E ratio of -265.93, a PEG ratio of 2.38 and a beta of 1.19. Bruker has a 1-year low of $28.53 and a 1-year high of $56.22. The company’s fifty day moving average price is $45.84 and its 200-day moving average price is $40.73. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The firm had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. During the same period last year, the company posted $0.76 earnings per share. The business’s quarterly revenue was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts anticipate that Bruker will post 2.69 EPS for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is currently -133.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.